잠복 결핵 감염 검출 시장 규모, 점유율, 동향 분석 보고서 : 브랜드별, 검사법별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Latent Tuberculosis Infection Detection Market Summary

The global latent tuberculosis infection detection market size was estimated at USD 1.91 billion in 2024, and is projected to reach USD 3.16 billion by 2033, growing at a CAGR of 5.81% from 2025 to 2033. The growth of the market is attributed to the increasing risk of developing active tuberculosis and the growing awareness among people to diagnose tuberculosis infection at an early stage.

Moreover, ongoing government initiatives to combat the threat of tuberculosis and the increasing introduction of novel diagnostic solutions are anticipated to fuel the latent tuberculosis infection (LTBI) detection market growth. Individuals with LTBI face a lifetime risk of reactivation, which is expected to be around 5% to 15%, with the majority of the population developing TB within the first 5 years. For those with LTBI, untreated HIV infection and no LTBI treatment can lead to a high risk of about 7%-10% per year, emphasizing the importance of timely intervention. In addition, most TB cases in the U.S. result from the progression of LTBI acquired over 2 years ago, highlighting the significance of addressing LTBI to prevent future cases.

The increasing funding for TB diagnosis programs is crucial in the fight against this global disease. The current funding for prevention, diagnosis, and treatment is insufficient to meet the demand, hindering progress in reducing incidence & mortality rates. For instance, an annual investment of USD 22 billion by 2027 was set, with an additional USD 5 billion for research, and only USD 5.8 billion was allocated for TB services, falling short of the required amounts to achieve global targets. Moreover, WHO emphasizes the need for sustained & increased funding to combat TB effectively.

Hence, the U.S. government has significantly increased its funding for TB initiatives, from USD 233 million in 2013 to USD 406 million in 2023. Investments in screening and preventive treatment have shown significant health & economic benefits, with a return on investment of up to USD 39 for every dollar spent. Hence, expanding investments in TB diagnosis programs is essential to improve access to diagnosis, treatment, and prevention to eliminate the TB epidemic by 2033. Moreover, the Global Fund contributes 76% of total international funding for TB, having allocated USD 9.2 billion toward prevention & treatment programs and an extra USD 1.5 billion for TB/HIV initiatives by June 2023. In countries receiving support from the Global Fund, TB-related fatalities have decreased by 36% from 2002 to 2022.

Moreover, the increasing number of elderly individuals worldwide poses a major hurdle in the control of TB within this age group. The rates of TB case detection & incidence are particularly high among older adults, emphasizing the importance of incorporating specific measures in TB response strategies to address their increased risk. In the Western Pacific, where the population is aging rapidly, there has been a notable increase in TB cases among older individuals, propelling the need for customized approaches to diagnosis, treatment, and care for this vulnerable demographic. This is expected to improve the need for the development of effective & efficient diagnostics to meet the rising demand for management among older populations.

However, the regulatory framework for approvals poses major restraints on the growth rate of the pharmaceutical, biotechnology, and medical technology industries. Globally, usage & safety profiles of diagnostic tests vary and are evaluated by health regulatory agencies of each country differently. This makes the approval of novel products slower.

Global Latent Tuberculosis Infection Detection Market Report Segmentation

This report forecasts revenue & volume growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the latent tuberculosis infection detection market report based on brand, test, application, end use, and region:

• Brand Outlook (Volume, Thousand Tests; Revenue, USD Million, 2021 - 2033)
• QFT-Plus (QuantiFERON-TB Gold Plus)
• Others
• Test Outlook (Volume, Thousand Tests; Revenue, USD Million, 2021 - 2033)
• Tuberculin Skin Test (TST)
• Interferon Gamma Released Assay (IGRA)
• Application Outlook (Volume, Thousand Tests; Revenue, USD Million, 2021 - 2033)
• Household Contacts with Pulmonary TB
• PLHIV
• Others
• End Use Outlook (Volume, Thousand Tests; Revenue, USD Million, 2021 - 2033)
• Diagnostic Laboratories
• Hospitals/Clinics
• Academic & Research Institutions
• Regional Outlook (Volume, Thousand Tests; Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Belgium
  • Finland
  • Luxembourg
  • Iceland
  • Netherlands
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Singapore
  • Bangladesh
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Latent Tuberculosis Infection Detection Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Method
    • 1.1.1.2. Test Segment
    • 1.1.1.3. Application Segment
    • 1.1.1.4. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Latent Tuberculosis Infection Detection Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Brand Snapshot
• 2.3. Test Snapshot
• 2.4. End Use Snapshot
• 2.5. Application Snapshot
• 2.6. Competitive Landscape Snapshot

Chapter 3. Latent Tuberculosis Infection Detection Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Increasing risk of developing active tuberculosis infection from LTBI
  • 3.4.2. Increasing funding programs to promote TB diagnosis
  • 3.4.3. Favorable government initiatives for combating TB
  • 3.4.4. Surge in geriatric population
• 3.5. Market Restraint Analysis
  • 3.5.1. Presence of stringent rules and regulations pertaining to diagnosis
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Latent Tuberculosis Infection Detection Market: Brand Estimates & Trend Analysis

• 4.1. Global Latent Tuberculosis Infection Detection Market: Brand Dashboard
• 4.2. Global Latent Tuberculosis Infection Detection Market: Brand Movement Analysis
• 4.3. Global Latent Tuberculosis Infection Detection Market by brand, Revenue
• 4.4. QFT-Plus (QuantiFERON-TB Gold Plus)
  • 4.4.1. QFT-Plus (QuantiFERON-TB Gold Plus) market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
• 4.5. Others
  • 4.5.1. Others market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)

Chapter 5. Latent Tuberculosis Infection Detection Market: Test Estimates & Trend Analysis

• 5.1. Global Latent Tuberculosis Infection Detection Market: Test Dashboard
• 5.2. Global Latent Tuberculosis Infection Detection Market: Test Movement Analysis
• 5.3. Global Latent Tuberculosis Infection Detection Market by Test, Revenue
• 5.4. Tuberculin Skin Test (TST)
  • 5.4.1. Tuberculin Skin Test (TST) market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
• 5.5. Interferon Gamma Released Assay (IGRA)
  • 5.5.1. Interferon Gamma Released Assay (IGRA) market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)

Chapter 6. Latent Tuberculosis Infection Detection Market: Application Estimates & Trend Analysis

• 6.1. Global Latent Tuberculosis Infection Detection Market: Application Dashboard
• 6.2. Global Latent Tuberculosis Infection Detection Market: Application Movement Analysis
• 6.3. Global Latent Tuberculosis Infection Detection Market by Application, Revenue
• 6.4. Household Contacts with Pulmonary TB
  • 6.4.1. Household contacts with pulmonary TB market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
• 6.5. PLHIV
  • 6.5.1. PLHIV market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)

Chapter 7. Latent Tuberculosis Infection Detection Market: End Use Estimates & Trend Analysis

• 7.1. Global Latent Tuberculosis Infection Detection Market: End Use Dashboard
• 7.2. Global Latent Tuberculosis Infection Detection Market: End Use Movement Analysis
• 7.3. Global Latent Tuberculosis Infection Detection Market by End Use, Revenue
• 7.4. Diagnostic Laboratories
  • 7.4.1. Diagnostic laboratories market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
• 7.5. Hospitals/Clinics
  • 7.5.1. Hospitals/Clinics market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
• 7.6. Academic & Research Institutions
  • 7.6.1. Academic & research institutions market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)

Chapter 8. Latent Tuberculosis Infection Detection Market: Regional Estimates & Trend Analysis by Product Type, Technology, and End Use

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.4.9. Netherlands
    • 8.4.9.1. Key country dynamics
    • 8.4.9.2. Regulatory framework/ reimbursement structure
    • 8.4.9.3. Competitive scenario
    • 8.4.9.4. Netherlands market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.4.10. Belgium
    • 8.4.10.1. Key country dynamics
    • 8.4.10.2. Regulatory framework/ reimbursement structure
    • 8.4.10.3. Competitive scenario
    • 8.4.10.4. Belgium market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.4.11. Finland
    • 8.4.11.1. Key country dynamics
    • 8.4.11.2. Regulatory framework/ reimbursement structure
    • 8.4.11.3. Competitive scenario
    • 8.4.11.4. Finland market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.4.12. Luxembourg
    • 8.4.12.1. Key country dynamics
    • 8.4.12.2. Regulatory framework/ reimbursement structure
    • 8.4.12.3. Competitive scenario
    • 8.4.12.4. Luxembourg market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.4.13. Iceland
    • 8.4.13.1. Key country dynamics
    • 8.4.13.2. Regulatory framework/ reimbursement structure
    • 8.4.13.3. Competitive scenario
    • 8.4.13.4. Iceland market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.5.7. Singapore
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Regulatory framework/ reimbursement structure
    • 8.5.7.3. Competitive scenario
    • 8.5.7.4. Singapore market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.5.8. Bangladesh
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Regulatory framework/ reimbursement structure
    • 8.5.8.3. Competitive scenario
    • 8.5.8.4. Bangladesh market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million, Volume in Thousand Tests)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2023
  • 9.3.4. QIAGEN
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. BIOMERIEUX
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Oxford Immunotec
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. SD Biosensor, INC.
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Wantai BioPharm
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Lionex GmbH
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Sanofi
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Serum Institute of India Pvt. Ltd
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. ARKRAY, Inc.
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Par Pharmaceutical, Inc.
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Product benchmarking
    • 9.3.13.4. Strategic initiatives